Management of myelodysplastic syndromes: 2008 update

ONCOLOGY

Volumn 22, Issue 12, 2008, Pages 1344-1352

  Scott, Bart L ^a   Estey, Eli ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; THYMOCYTE ANTIBODY;

BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; GRANULOCYTOPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON CHELATION; MACROCYTIC ANEMIA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OPTIMAL DRUG DOSE; PATIENT MONITORING; PROGNOSIS; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATINICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IRON CHELATING AGENTS; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 57449083973     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Rollison DE, Howlader N, Smith MT, et al: Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112:45-52, 2008.
2. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002.
3. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51-189-199, 1982.
4. Malcovati L, Porta MG, Pascutto C, et al: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23:7594-7603, 2005.
5. Howe RB, Porwit-MacDonald A, Wanat R, et al: The WHO classification of MDS does make a difference. Blood 103:3265-3270, 2004.
6. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes (erratum appears in Blood 91:1100, 1998). Blood 89:2079-2088, 1997.
7. Malcovati L, Della Porta MG, Cazzola M: Predicting survival and leukemia evolution in patients with myelodysplastic syndrome. Haematologica 91:1588-1590, 2006.
8. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007.
9. Scott BL, Wells DA, Loken MR, et al: Validation of a flow cytometric scoring system as a prognostic indicator for post-transplant outcome in patients with MDS. Blood July 7 2008 (epub ahead of print).
10. Yamaguchi N, Ito Y, Ohyashiki K: Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes. Ann Hematol 84:383-388, 2005.
11. Zeidman A, Sokolover N, Fradin Z, et al: Platelet function and its clinical significance in the myelodysplastic syndromes. Hematol J 5:234-238, 2004.
12. Negrin RS, Haeuber DH, Nagler A, et al: Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. Ann Intern Med 110:976-984, 1989.
13. Thompson JA, Gilliland DG, Prchal JT, et al: Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95:1175-1179, 2000.
14. Leitch HA: Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 31(suppl 3):S7-S9, 2007.
15. Smith RE Jr, Aapro MS, Ludwig H, et al: Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26:1040-1050, 2008.
16. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al: A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 120:1037-1046, 2003.
17. Jädersten M, Montgomery SM, Dybedal I, et al: Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106:803-811, 2005.
18. Park S, Grabar S, Kelaidi C, et al: Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 111:574-582, 2008.
19. Miller KB, Kim HT, Greenberg P, et al: Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): Results of the ECOG-CLSG trial (E1996) (abstract 70). Blood 104:24a, 2004.
20. Jädersten M, Malcovati L, Dybedal I, et al: Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26:3607-3613, 2008
21. Park S, Grabar S, Kelaidi C, et al: Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 111:574-582, 2008.
22. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68-75, 1998.
23. Molldrem JJ, Leifer E, Bahceci E, et al: Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndrome [summary for patients in Ann Intern Med 137:1-27, 2002]. Ann Intern Med 137:156-163, 2002.
24. Saunthararajah Y, Nakamura R, Wesley R, et al: A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102:3025-3027, 2003.
25. Stadler M, Germing U, Kliche KO, et al: A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18:460-465, 2004.
26. Sloand EM, Wu CO, Greenberg P, et al: Factors affecting response and survival in patients with myelodysplasia treated with immunosupporessive therapy. J Clin Oncol 26:2505-2511, 2008.
27. Steensma DP, Dispenzieri A, Moore SB, et al: Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101:2156-2158, 2003.
28. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006.
29. Raza A, Reeves JA, Feldman EJ, et al: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:86-93, 2008.
30. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440, 2002.
31. Silverman LR, McKenzie DR, Peterson BL, et al: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-3903, 2006.
32. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006.
33. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57, 2007.
34. Kantarjian H, Beran M, Cortes J, et al: Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 106:1099-1109, 2006.
35. Kantarjian HM, O'Brien S, Huang X, et al: Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: Comparison with historical experience. Cancer 109:1133-1137, 2007.
36. Deeg HJ, Storer B, Slattery JT, et al: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201-1207, 2002.
37. Sorror ML, Sandmaier BM, Storer BE, et al: Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25:4246-4254, 2007.
38. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585, 2004.
39. Martino R, Iacobelli S, Brand R, et al: Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836-846, 2006.
40. Scott BL, Sandmaier BM, Storer B, et al: Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 20:128-135, 2006.